Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders
Abstract Background Major efforts have been made in the last decade to develop and improve therapies for proximal spinal muscular atrophy (SMA). The introduction of Nusinersen/Spinraza™ as an antisense oligonucleotide therapy, Onasemnogene abeparvovec/Zolgensma™ as an AAV9-based gene therapy and Ris...
Main Authors: | Sibylle Jablonka, Luisa Hennlein, Michael Sendtner |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-01-01
|
Series: | Neurological Research and Practice |
Subjects: | |
Online Access: | https://doi.org/10.1186/s42466-021-00162-9 |
Similar Items
-
Copy Number Variations in the Survival Motor Neuron Genes: Implications for Spinal Muscular Atrophy and Other Neurodegenerative Diseases
by: Matthew E R Butchbach, et al.
Published: (2016-03-01) -
In Search of a Cure: The Development of Therapeutics to Alter the Progression of Spinal Muscular Atrophy
by: Kristine S. Ojala, et al.
Published: (2021-02-01) -
Pyramidal signs in a Caucasian patient with spinal muscular atrophy: a case report
by: Yu Wan, et al.
Published: (2016-12-01) -
Comparison of neurofilament light and heavy chain in spinal muscular atrophy and amyotrophic lateral sclerosis: A pilot study
by: Jin‐Yue Li, et al.
Published: (2023-05-01) -
Feasibility and effectiveness of a novel dynamic arm support in persons with spinal muscular atrophy and duchenne muscular dystrophy
by: Mariska M. H. P. Janssen, et al.
Published: (2021-05-01)